Use of Chinese Herb Medicine in Cancer Patients: a Survey in Southwestern China

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2012 Sep 22

PMID 22997534

Citations 25

Authors

Tai-Guo Liu

Shao-Quan Xiong

Yan Yan

Hong Zhu

Cheng Yi

Affiliations

Soon will be listed here.

Abstract

Chinese herb medicine (CHM) is the most commonly reported traditional Chinese medicine (TCM) modality. This study aimed to assess the prevalence and associated factors of CHM use in cancer patients in southwestern China. Cancer patients from eleven comprehensive cancer centers were asked to complete a structured questionnaire. Of 587 available replies, 53.0% used CHM. Multiple logistic regression analysis showed that educational level, stage of disease, duration of cancer since diagnosis, marital status, and previous use of CHM were strongly associated with CHM use after cancer diagnosis. The source of information about CHM was mainly from media and friends/family. CHM products were used without any consultation with a TCM practitioner by 67.5% of users. The majority used CHM to improve their physical and emotional well-beings and to reduce cancer therapy-induced toxicities. About 4.5% patients reported side effects of CHM. This survey revealed a high prevalence of CHM use among cancer patients. However, these patients did not get sufficient consultation about the indications and contradictions of these drugs. It is imperative for oncologists to communicate with their cancer patients about the usage of CHM so as to avoid the potential side effects.

Citing Articles

Chinese herbal medicine for the treatment of intestinal cancer: preclinical studies and potential clinical applications.

Zhang J, Wu Y, Tian Y, Xu H, Lin Z, Xian Y Mol Cancer. 2024; 23(1):217.

PMID: 39354520 PMC: 11443726. DOI: 10.1186/s12943-024-02135-3.

The intention of utilization and experience toward traditional Chinese medicine among breast cancer patients in the early and late stages: a qualitative study.

Chen K, Chung K, Hsu C BMC Complement Med Ther. 2023; 23(1):226.

PMID: 37420247 PMC: 10329334. DOI: 10.1186/s12906-023-04054-0.

Use of Medicinal Plants by Cancer Patients Under Chemotherapy in the Northwest of Morocco (Rabat Area) : Cross-Sectional Study.

El Orfi N, Boutayeb S, Haddou Rahou B, Errihani H J Evid Based Integr Med. 2022; 27:2515690X221128036.

PMID: 36254459 PMC: 9580094. DOI: 10.1177/2515690X221128036.

Navigating communication between conventional medicine and traditional Chinese medicine: a case study of cancer patients in Hong Kong.

Pun J, Wong W Support Care Cancer. 2022; 30(7):5729-5735.

PMID: 35325313 DOI: 10.1007/s00520-022-06986-8.

Integrative RNA-Seq and ATAC-Seq Analysis Reveals the Migration-Associated Genes Involved in Antitumor Effects of Herbal Medicine Feiyanning on Lung Cancer Cells.

Wang C, Li P, Peng Y, Liu R, Wu X, Tan S Front Genet. 2022; 12:799099.

PMID: 34992637 PMC: 8724546. DOI: 10.3389/fgene.2021.799099.

References

Gao J, Morgan W, Sanchez-Medina A, Corcoran O . The ethanol extract of Scutellaria baicalensis and the active compounds induce cell cycle arrest and apoptosis including upregulation of p53 and Bax in human lung cancer cells. Toxicol Appl Pharmacol. 2011; 254(3):221-8. DOI: 10.1016/j.taap.2011.03.016. View

Lin H, Liu J, Zhang Y . Developments in cancer prevention and treatment using traditional Chinese medicine. Front Med. 2011; 5(2):127-33. DOI: 10.1007/s11684-011-0137-7. View

Lukman S, He Y, Hui S . Computational methods for Traditional Chinese Medicine: a survey. Comput Methods Programs Biomed. 2007; 88(3):283-94. DOI: 10.1016/j.cmpb.2007.09.008. View

Min R, Tong J, Wenjun Y, Wenhu D, Xiaojian Z, Jiacai H . Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-kappaB pathway. Phytother Res. 2008; 22(3):407-15. DOI: 10.1002/ptr.2340. View

McCulloch M, See C, Shu X, Broffman M, Kramer A, Fan W . Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006; 24(3):419-30. DOI: 10.1200/JCO.2005.03.6392. View

Chan A, Chan A, Tan H, Lin T, Shih V, Ching T . Clinical outcomes for cancer patients using complementary and alternative medicine. Altern Ther Health Med. 2012; 18(1):12-7. View

Swisher E, Cohn D, Goff B, Parham J, Herzog T, Rader J . Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol. 2002; 84(3):363-7. DOI: 10.1006/gyno.2001.6515. View

Teng L, Jin K, He K, Bian C, Chen W, Fu K . Use of complementary and alternative medicine by cancer patients at Zhejiang University Teaching Hospital Zhuji Hospital, China. Afr J Tradit Complement Altern Med. 2011; 7(4):322-30. PMC: 3005395. DOI: 10.4314/ajtcam.v7i4.56699. View

Liu J, Chen Z . Traditional Chinese medicine in the new century. Front Med. 2011; 5(2):111-4. PMC: 7088844. DOI: 10.1007/s11684-011-0125-y. View

10.

Zhao P, Dai M, Chen W, Li N . Cancer trends in China. Jpn J Clin Oncol. 2010; 40(4):281-5. DOI: 10.1093/jjco/hyp187. View

11.

Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Scott J, Panteli V . Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005; 16(4):655-63. DOI: 10.1093/annonc/mdi110. View

12.

Rausch S, Winegardner F, Kruk K, Phatak V, Wahner-Roedler D, Bauer B . Complementary and alternative medicine: use and disclosure in radiation oncology community practice. Support Care Cancer. 2010; 19(4):521-9. DOI: 10.1007/s00520-010-0846-5. View

13.

Ezeome E, Anarado A . Use of complementary and alternative medicine by cancer patients at the University of Nigeria Teaching Hospital, Enugu, Nigeria. BMC Complement Altern Med. 2007; 7:28. PMC: 2034592. DOI: 10.1186/1472-6882-7-28. View

14.

Yang C, Chien L, Tai C . Use of complementary and alternative medicine among patients with cancer receiving outpatient chemotherapy in Taiwan. J Altern Complement Med. 2008; 14(4):413-6. DOI: 10.1089/acm.2007.7181. View

15.

Boon H, Westlake K, Stewart M, Gray R, Fleshner N, Gavin A . Use of complementary/alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics. Urology. 2003; 62(5):849-53. DOI: 10.1016/s0090-4295(03)00668-x. View

16.

Guo Z, Jia X, Liu J, Liao J, Yang Y . Herbal medicines for advanced colorectal cancer. Cochrane Database Syst Rev. 2012; (5):CD004653. DOI: 10.1002/14651858.CD004653.pub2. View

17.

Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K . Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003; 51(5):403-6. DOI: 10.1007/s00280-003-0585-0. View

18.

Tas F, Ustuner Z, Can G, Eralp Y, Camlica H, Basaran M . The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients. Acta Oncol. 2005; 44(2):161-7. DOI: 10.1080/02841860510007549. View

19.

Yang L, Parkin D, Ferlay J, Li L, Chen Y . Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005; 14(1):243-50. View

20.

Zhou X, Peng Y, Liu B . Text mining for traditional Chinese medical knowledge discovery: a survey. J Biomed Inform. 2010; 43(4):650-60. DOI: 10.1016/j.jbi.2010.01.002. View